{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:54:48Z","timestamp":1789012488440,"version":"build-2803163510"},"reference-count":26,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cell lymphoma (MCL), R-BAC was associated with a complete remission rate of 91% and 2-year progression-free survival (PFS) of 81% (95% confidence interval [CI], 68-89). Here, we report the long-term survival outcomes, late toxicities, and results of minimal residual disease (MRD) evaluation. After a median follow-up of 86\u00a0months (range, 57-107\u00a0months), the median overall survival (OS) and PFS were not reached. The 7-year PFS and OS rates were 55% (95%\u00a0CI, 41-67), and 63% (95%\u00a0CI, 49-74), respectively. Patients who responded (n\u00a0= 53) had a 7-year PFS of 59% (95%\u00a0CI, 44-71), with no relapse or progression registered after the sixth year. In the multivariate analysis, blastoid\/pleomorphic morphology was the strongest adverse predictive factor for PFS (P\u00a0= .04). Patients with an end of treatment negative MRD had better, but not significant, outcomes for both PFS and OS than patients with MRD-positive (P\u00a0= 0.148 and P\u00a0= 0.162, respectively). There was no signal of late toxicity or an increase in secondary malignancies during the prolonged follow-up. In conclusion, R-BAC, which was not followed by maintenance therapy, showed sustained efficacy over time in older patients with MCL. Survival outcomes compare favorably with those of other immunochemotherapy regimens (with or without maintenance), including combinations of BTK inhibitors upfront. This study was registered with EudraCT as 2011-005739-23 and at www.clinicaltrials.gov as #NCT01662050.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009744","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T15:03:46Z","timestamp":1683903826000},"page":"3916-3924","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL"],"prefix":"10.1182","volume":"7","author":[{"given":"Maria Chiara","family":"Tisi","sequence":"first","affiliation":[{"name":"1Hematology Unit, San Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-1138","authenticated-orcid":false,"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and AOU Maggiore della Carit\u00e0, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"3Oncohematology Azienda Ospedali Riuniti Villa Sofia-V. Cervello Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-2805","authenticated-orcid":false,"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[{"name":"4Unit of Clinical Epidemiology, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza and CPO Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"5Hematology 1 U, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy\/AOU Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"6Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"7Hematology, Ospedale di Ravenna, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"8Hematology, Citt\u00e0' della Salute e della Scienza University Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Celli","sequence":"additional","affiliation":[{"name":"9Hematology, Ospedale degli Infermi, Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Careggi Hospital and University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"11UOC Ematologia, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9623","authenticated-orcid":false,"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"12Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Chini","sequence":"additional","affiliation":[{"name":"13Oncology ASST-settelaghi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[{"name":"14UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-5324","authenticated-orcid":false,"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"15Hematology, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[{"name":"16Hematology, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-1015","authenticated-orcid":false,"given":"Roberta","family":"Sciarra","sequence":"additional","affiliation":[{"name":"17Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bruna","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and AOU Maggiore della Carit\u00e0, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-9603","authenticated-orcid":false,"given":"Martina","family":"Ferrante","sequence":"additional","affiliation":[{"name":"18Hematology 1 U, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Alessandro","family":"Pileri","sequence":"additional","affiliation":[{"name":"19Division of Haematopathology, IEO, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-3775","authenticated-orcid":false,"given":"Francesca Maria","family":"Quaglia","sequence":"additional","affiliation":[{"name":"20Section of Hematology, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[{"name":"21Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Ematologia Reggio Calabria, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"22Hematology, Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[{"name":"23Hematology Department, Santa Maria della Misericordia Hospital - ASUFC, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[{"name":"24Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[{"name":"25Hematology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"26Hematology, AUSL\/IRCCS Reggio Emilia, Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"20Section of Hematology, Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"4","key":"2023080716350766600_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9873","key":"2023080716350766600_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2023080716350766600_bib3","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine\u2013rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023080716350766600_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023080716350766600_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2023080716350766600_bib6","unstructured":"National Comprehensive Cancer Networ . NCCN Clinical Practice Guidelines in Oncology: B-cell lymphoma; version 5. 2022. Accessed 3 February 2023. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines."},{"issue":"1","key":"2023080716350766600_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"issue":"suppl_4","key":"2023080716350766600_bib8","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2023080716350766600_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","article-title":"The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma","volume":"48","author":"Visco","year":"2012","journal-title":"Blood Cells Mol Dis"},{"issue":"23","key":"2023080716350766600_bib10","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/cancers13236089","article-title":"Rituximab and Bendamustine (BR) compared with rituximab, bendamustine, and cytarabine (R-BAC) in previously untreated elderly patients with mantle cell lymphoma","volume":"13","author":"Bega","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"26","key":"2023080716350766600_bib11","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2023080716350766600_bib12","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"5","key":"2023080716350766600_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023080716350766600_bib14","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/HS9.0000000000000347","article-title":"Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network","volume":"4","author":"Drandi","year":"2020","journal-title":"Hemasphere"},{"issue":"6","key":"2023080716350766600_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"Suppl 1","key":"2023080716350766600_bib16","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2021-145421","article-title":"Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma [abstract]","volume":"138","author":"Visco","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023080716350766600_bib17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023080716350766600_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized european mcl elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023080716350766600_bib19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023080716350766600_bib20","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10044","key":"2023080716350766600_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"2023080716350766600_bib22","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023080716350766600_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2023080716350766600_bib24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2023080716350766600_bib25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2023080716350766600_bib26","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3916\/2069893\/blooda_adv-2023-009744-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3916\/2069893\/blooda_adv-2023-009744-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T20:34:58Z","timestamp":1702413298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/3916\/495780\/Long-term-follow-up-of-rituximab-plus-bendamustine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009744","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}